Goldline Pharmaceutical SME IPO Review
Goldline Pharmaceutical SME IPO has been reviewed by 1 analyst, and the overall consensus is May Apply — carrying a score of 60. Out of the 1 analysts who have covered this IPO, 0 recommend subscribing while 1 advises caution or avoidance — reflecting a mixed view from the analyst community.
The issue is priced in the band of ₹41-43 per share , with a minimum application size of 3000 shares (minimum investment of approximately ₹129,000 at the upper band) . The subscription window runs from 12 May 2026 to 14 May 2026. As of now, the grey market premium (GMP) for Goldline Pharmaceutical SME IPO is quoting at ₹18 (42%), which gives a preliminary sense of how the street is pricing the listing — though GMP is unofficial and can swing sharply before the listing date. Scroll down for the full analyst breakdown and analyst-wise verdicts.
Table of Contents
Recommend Subscribe
Based on 1 analyst reviews
Higher consensus indicates broader analyst agreement.
Analyst Review
Latest IPO Reviews
Frequently Asked Questions
Should I apply for Goldline Pharmaceutical SME IPO?
Based on analyst coverage tracked on this page, the overall verdict for Goldline Pharmaceutical SME IPO is May Apply. Out of 1 analyst who have reviewed this IPO, 0 recommend subscribing. Always cross-check with the full analyst reviews below and consult a SEBI-registered advisor before making any investment decision.
What does the score of 60 mean for Goldline Pharmaceutical SME IPO?
The score of 60 is an aggregate of all analyst ratings tracked for Goldline Pharmaceutical SME IPO. A score in this range reflects mixed views — some analysts are positive while others are cautious. Scroll down to read individual analyst verdicts for more context.
What are the listing gain expectations for Goldline Pharmaceutical SME IPO?
The grey market premium (GMP) for Goldline Pharmaceutical SME IPO is currently ₹18 (42%), which suggests the street is pricing a listing above the issue price. Keep in mind that GMP is an unofficial, unregulated indicator and can shift sharply in the 24–48 hours before listing. Track the live GMP page for real-time updates.
What is the price band and lot size of Goldline Pharmaceutical SME IPO?
Goldline Pharmaceutical SME IPO is priced at ₹41-43 per share. The minimum lot size is 3000 shares, making the minimum investment approximately ₹129,000 at the upper end of the price band. The subscription window is open from 12 May 2026 to 14 May 2026.
Explore Goldline Pharmaceutical SME IPO Further
Track every stage of this IPO:
Discussion 0
No comments yet
Be the first to share your thoughts!